Isa101b-Hn-01-17 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Of Cemiplimab Versus The Combination Of Cemipilmab With Isa101b In The Treatment Of Subjects With Hpv16-Positive Platin-Resistant Oropharyngeal Cancer (Opc)
Posted Date: Jun 10, 2019
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
To evaluate if the addition of ISA101b to cemiplimab results in improved overall response rate (ORR) compared to cemiplimab alone
Criteria:
At Least 18 Years Of Age, Recurrent/Metastatic Hpv16+ Oropharyngeal Cancer, Tumor Progression/Reoccurance After Platinum Based Chemotherapy, No Chemo Within 28 Days Of First Study Treatment
Keywords:
Oropharyngeal Cancer, Head And Neck Cancer, Hpv16+
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com